Assignee
ABBVIE BIOTHERAPEUTICS INC
US·31 granted patents·35 pending applications·160 citations·filing 2012–2024
Top patents by PatentIndex Score
66 records- 0196US9914783B1Anti-PD-1 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Mar 13, 2018·61 cites·17 claims
- 0292US10233258B2Bispecific binding proteins that bind CD40 and mesothelinABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Mar 19, 2019·16 cites·10 claims
- 0389US9260528B2DAC HYP compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Feb 16, 2016·7 cites·8 claims
- 0488US10875921B2Anti-4-1BB antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Dec 29, 2020·4 cites·18 claims
- 0588US10053720B2Vectors and host cells comprising a modified SV40 promoter for protein expressionABBVIE BIOTHERAPEUTICS INC·Filed 2016·Granted Aug 21, 2018·5 cites·19 claims
- 0688US10040864B2Anti-OX40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Aug 7, 2018·4 cites·18 claims
- 0788US10023645B1Anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Jul 17, 2018·5 cites·11 claims
- 0888US9676860B2DAC HYP compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Jun 13, 2017·7 cites·8 claims
- 0988US9587007B2CTLA4 proteins and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2014·Granted Mar 7, 2017·8 cites·19 claims
- 1087US10011657B2Anti-CS1 antibodies and antibody drug conjugatesABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Jul 3, 2018·4 cites·16 claims
- 1187US9815903B2DAC HYP compositionsABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Nov 14, 2017·5 cites·12 claims
- 1287US9340619B2DAC HYP compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted May 17, 2016·6 cites·4 claims
- 1387US9315573B2Anti-TNF-alpha antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2014·Granted Apr 19, 2016·9 cites·36 claims
- 1486US8883971B2CTLA4 proteins and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Granted Nov 11, 2014·7 cites·19 claims
- 1584US9815893B2Anti-VEGF antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Granted Nov 14, 2017·6 cites·13 claims
- 1681US2023321271A1ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USEABBVIE BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1780US2022112304A1Anti-ox40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1879US9175081B2Therapeutic use of anti-CS1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Granted Nov 3, 2015·2 cites·36 claims
- 1979US2022119542A1Anti-cd40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2078US10400041B2Nucleic acid molecules encoding anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Sep 3, 2019·1 cites·20 claims
- 2177US10519243B2Anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Dec 31, 2019·1 cites·9 claims
- 2277US2021277137A1Anti-cd40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2376US12478689B2Anti-CD19 antibody drug conjugatesABBVIE BIOTHERAPEUTICS INC·Filed 2024·Granted Nov 25, 2025·0 cites·13 claims
- 2476US12121589B2Anti-CD19 antibody drug conjugatesABBVIE BIOTHERAPEUTICS INC·Filed 2023·Granted Oct 22, 2024·0 cites·3 claims
- 2576US10604584B2Anti-OX40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Granted Mar 31, 2020·0 cites·2 claims
- 2675US2021017289A1Anti-ox40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2774US2021024642A1Anti-cd40 antibody and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2873US10844131B2Anti-CD40 antibodyABBVIE BIOTHERAPEUTICS INC·Filed 2019·Granted Nov 24, 2020·0 cites·9 claims
- 2973US2020181282A1Anti-ox40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3072US10597460B2Anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Granted Mar 24, 2020·0 cites·2 claims
- 3171US10730953B2Anti-PD-1 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Granted Aug 4, 2020·0 cites·2 claims
- 3270US10556962B2Anti-OX40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Feb 11, 2020·0 cites·15 claims
- 3370US9072725B2Method for treating psoriasisABBVIE BIOTHERAPEUTICS INC·Filed 2014·Granted Jul 7, 2015·1 cites·3 claims
- 3469US2020157230A1Dac hyp compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3569US2020031929A1Therapeutic use of anti-cs1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3667US2020317808A1Anti-pd-1 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3767US2018346593A1Anti-ox40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3866US9279016B2Methods for identifying antibodies with reduced immunogenicityABBVIE BIOTHERAPEUTICS INC·Filed 2013·Granted Mar 8, 2016·1 cites·12 claims
- 3963US2022211846A1Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancersABBVIE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4063US2020308290A1Anti-cd25 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4162US10308713B2Anti-CS1 antibodies and antibody drug conjugatesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Jun 4, 2019·0 cites·20 claims
- 4262US2018127506A1Dac hyp compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4361US10442859B2Therapeutic use of anti-CS1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Oct 15, 2019·0 cites·12 claims
- 4460US2019062797A1Vectors and host cells comprising a modified SV40 promoter for protein expressionABBVIE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4559US10150814B2Fc variants with improved complement activationABBVIE BIOTHERAPEUTICS INC·Filed 2014·Granted Dec 11, 2018·0 cites·14 claims
- 4659US2017342150A1Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4758US2017348429A1ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USEABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4857US2014322201A1Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 4957US2018148513A1Anti-pd-1 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 5056US2015051081A1Method of screening complex protein libraries to identify altered propertiesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 66 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ABBVIE BIOTHERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →